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Purpose: Ovarian cancer is a devastating disease and biomarkers for its early diagnosis are
urgently required. Serum may be a valuable source of biomarkers that may be revealed by
proteomic profiling. Herein, complementary serum protein profiling strategies were employed
for discovery of biomarkers that could discriminate cases of malignant and benign ovarian
cancer.
Experimental design: Identically collected and processed serum samples from 22 cases of
invasive epithelial ovarian cancer, 45 benign ovarian neoplasms, and 64 healthy volunteers
were subjected to immunodepletion and protein equalization coupled to 2D-DIGE/MS and
multidimensional fractionation coupled to SELDI-TOF profiling with MS/MS for protein iden-
tification. Selected candidates were verified by ELISA in samples from malignant (n = 70) and
benign (n = 89) cases and combined marker panels tested against serum CA125.
Results: Both profiling platforms were complementary in identifying biomarker candidates,
four of which (A1AT, SLPI, APOA4, VDBP) significantly discriminatedmalignant from benign
cases. However, no combination of markers was as good as CA125 for diagnostic accuracy.
SLPI was further tested as an early marker using prediagnosis serum samples. While it rose in
cases toward diagnosis, it did not discriminate prediagnosis cases from controls.
Conclusions and clinical relevance: The candidate biomarkers warrant further validation in
independent sample sets.
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 Additional supporting information may be found in the online version of this article atthe publisher’s web-site
1 Introduction
Every year there are over 200 000 new cases of ovarian can-
cer and 125 000 deaths worldwide [1]. The prognosis is poor
Correspondence: Dr. John F. Timms, Cancer Proteomics Labora-
tory, Institute for Women’s Health, University College London,
Cruciform Building 1.1.09, Gower Street, London, WC1E 6BT, UK
E-mail: john.timms@ucl.ac.uk
Abbreviations: ROC, receiver operating characteristic;UKCTOCS,
UK Collaborative Trial of Ovarian Cancer Screening; UKOPS,
United Kingdom Ovarian Cancer Population Study; VDBP, vita-
min D binding protein
reflecting the late stage at diagnosis and lack of an estab-
lished screening programme. Transvaginal ultrasound and
serum CA125 are the main diagnostic tests for primary inva-
sive epithelial ovarian/tubal cancers in symptomatic patients.
However, CA125 is not cancer-specific and may be elevated
in benign gynecological conditions such as benign ovarian
neoplasms and endometriosis, necessitating further investi-
gation by imaging [2]. In addition, not all early-stage tumors
generate sufficient CA125 for diagnostic purposes. Conse-
quently, biomarkers with improved accuracy for detecting
and diagnosing ovarian cancer are urgently required. While
several marker panels and algorithms have been reported
for differential diagnosis [3–11], there is as yet insufficient
evidence to support their wider clinical use, particularly for
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Clinical Relevance
We have used two complementary serum protein
profiling strategies to identify novel biomarkers for
the differential diagnosis of ovarian cancer and fur-
ther tested one of these as an early detection marker
using prediagnosis samples. Markers SLPI, VDBP,
A1AT, and APOA4 all significantly discriminated
malignant from benign cases, although did not add
to CA125 in multimarker models in this cohort of
patients where CA125 performed exceptionally well.
One of the candidate markers, SLPI, was raised in the
lead up to diagnosis using prediagnostic samples,
but did not significantly discriminate cases from
matched controls. The further validation of these
candidate biomarkers in more representative patient
cohorts is warranted.
early detection of ovarian cancer. It is noteworthy that sev-
eral of these panels include CA125, which provides much
of the discriminating power. Notably, the serummarker HE4
holds promise and appears to complement CA125 in discrim-
inating cancer from benign conditions in premenopausal
women.
Analysis of serum/plasma proteomes for biomarker dis-
covery remains challenging owing to the extreme dynamic
range of expression of the constituent proteins and the fact
that a small number of highly abundant serumproteinsmake
up the majority of protein content. This has prompted re-
searchers to use multidimensional protein/peptide separa-
tions and depletion methods as part of profiling strategies.
Despite this, proteomic coverage is still limited and few if any
robust cancer biomarkers have been identified using classi-
cal proteomic profiling methods. The need for identical han-
dling of clinical samples is also of paramount importance in
order to avoid largely proteolysis-driven changes unrelated to
biological variation and has been highlighted by numerous
studies [12–17]. Finally, issues related to reproducibility and
the robustness of class-discriminating algorithms used for
proteomic biomarker discovery have also been raised [18,19].
Of the technologies employed, MALDI-TOF MS and
SELDI-TOF MS have the capability for high-throughput pro-
filing when linked to (semi-)automated sample processing,
though lack resolution and mass accuracy, as well as dy-
namic range and sensitivity, particularly when analyzing
complex samples such as body fluids. LC-MS/MS provides
higher mass accuracy and resolution, though it is inherently
low throughput. Similarly, quantitative 2DE, for example 2D-
DIGE, is a low-throughput technique, but has high quantita-
tive accuracy, multiplexing capacity, a broad linear dynamic
range of detection, and permits visualization of protein iso-
forms [20].
Herein, we have used two unbiased, complementary pro-
teomic approaches to profile a case control set of serum sam-
ples from theUKOvarianCancer PopulationStudy (UKOPS),
collected and handled according to a rigorous SOP. Immun-
odepletion of the seven most abundant proteins and pro-
tein equalization technology was applied to improve coverage
by 2D-DIGE profiling, while a semiautomated multidimen-
sional protein fractionation strategy incorporating protein
equalization was linked to SELDI-TOF profiling. Data were
filtered to find potential biomarkers that could discriminate
cases of malignant epithelial ovarian cancer from benign or
healthy controls. Several of the candidates were further vali-
dated using ELISA and compared with CA125.
2 Materials and methods
2.1 Subjects, sample collection, and handling
This biomarker discovery study was approved by the Joint
UCL/UCLH Committees on the Ethics of Human Research
(Committee A) (Reference No. 05/Q0505/58). Written in-
formed consent was obtained from all donors and no data
allowing identification of patients was provided. Women
were recruited into the UK Ovarian Cancer Population Study
(UKOPS) from ten NHS Trusts across the UK through gy-
naecological oncology departments. Serum samples from pa-
tients were collected between 2005 and 2009 prior to surgery
for an ovarian neoplasm, and the diagnosis of malignant or
benign ovarian neoplasm was confirmed by independent re-
view of notes and histopathology reports. Serum samples
came from women diagnosed with primary invasive epithe-
lial ovarian cancer (n = 70) or benign ovarian neoplasms
(n = 89) and from healthy age-matched controls (n = 173).
Healthy volunteers were recruited fromwomen attending an-
nual screening in the UK Collaborative Trial of Ovarian Can-
cer Screening (UKCTOCS) [21, 22] also between 2005 and
2009. They had no family history of ovarian cancer and no
diagnosis of a cancer during follow-up. Median and mean
ages, histological subtypes, and sample numbers for each
group are detailed in Table 1. All samples were collected and
processed identically as described [23].
One candidate biomarker was also tested as an
early marker in UKCTOCS prediagnosis samples and
matched controls. Use of these samples was approved
by the Joint UCL/UCLH Research Ethics Committee A
(Ref. 05/Q0505/57), with written informed consent obtained
from all donors and no data provided that allowed patient
identification. Trial participants at enrolment were post-
menopausal women aged 50–74 who had no family history
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Table 1. Case control samples used for study
Malignant Benign Healthy
Histological
subtype/
patient group
Stage I
(median
age = 62.6;
IQR
50.4–73.3)
Stage II
(median
age = 65.2;
IQR
54.7–66.5)
Stage III
(median
age = 63.9;
IQR
54.1–70.9)
Stage IV
(median
age = 69.2;
IQR
59.3–73.1)
Unstaged
(median
age =
41.2)
Total
(median
age = 63.9;
IQR
53.6–71.2)
Benign
(median
age = 58.7;
IQR
48.7–68.5)
Healthy
(median
age = 63.9;
IQR
59.2–69.1)
Serous
carcinoma
5 2 23 4 34
Endometrioid
carcinoma
7 2 4 1 14
Mucinous
carcinoma
5 2 7
Clear cell
carcinoma
3 2 1 1 7
Mixed carcinoma 3 1 4
Transitional cell
carcinoma
1 1
Adenocarcinoma
(unspecified)
3 2
Borderline 9 2
Benign 89
Healthy 173
Total 33 6 34 5 3 70 89 173
FIGO staging was used. IQR, inter-quartile range.
of ovarian cancer. All participants were "flagged" with the na-
tional agencies for cancer registrations and deaths using their
NHS number. Women subsequently diagnosed with ovarian
cancer (cases) were identified by cross-referencing with the
Health and Social Care Information Centre cancer registry
codes and death codes (ICD10 C56, C57.0) with diagnosis
confirmed by review of histopathology reports. The study set
comprised serum from women in the multimodal screening
arm of UKCTOCS [22]. There were two samples from each
of 49 women taken 3–14 months ("late") and >32 months
("early") prior to diagnosis of primary invasive or borderline
epithelial ovarian cancer that were subsequently grouped as
Type I + Borderline (BL) and Type II, based on morphology
and grade [24]. Matched noncancer controls from 25 women
(two samples each) were selected based on collection date, col-
lection centre, and age for Type II cases. The resulting study
set was 148 serum samples from 74women, 19 of whomwere
subsequently diagnosed with Type I or BL ovarian cancer and
30 of whom were subsequently diagnosed with Type II ovar-
ian cancer. Supporting Information Table 1 shows clinical,
lifestyle, and sample data for this study set.
2.2 Serum profiling
Two complementary profiling strategies were used (detailed
in Supporting Information Methods). The first used 2D-
DIGE analysis of a subset of 131 samples pooled (by equal
volume) according to clinical group: healthy (n = 64), benign
(n = 45), and malignant (n = 22). Three types of sample
preparation were analyzed: unfractionated sera (UnF), sera
immunodepleted of the seven most abundant proteins using
the HPLC-based Multiple Affinity Removal System (MARS;
Agilent), and sera subjected to ProteoMiner (PM) Protein
Enrichment (BioRad). The latter method relies on a large,
highly diverse bead-based library of combinatorial peptide
ligands, which simultaneously dilutes high-abundance
proteins and concentrates low-abundance proteins (protein
equalization) to improve coverage.
The three sample preparations were labelled with Cy-dyes
and run in a series of 2D-DIGE experiments to compare
the proteomes of the healthy, benign, and malignant serum
pools, essentially as described [25]. Samples (50 or 100 g
protein) were run in quadruplicate with Cy3 and Cy5
dye swapping against a Cy2-labeled standard run on each
large-format gel and comprised of a pool of all clinical
groups for the relevant preparation method. Gel images were
analyzed using DeCyder V5.0 software (GE Healthcare).
Briefly, standardized volumes for spots-matched across all
gels were averaged across replicates for each condition and
the ratios compared. Spots matching on all gels displaying a
1.5 average-fold change in abundance with p values <0.05
(Student t-test) were selected for automated picking, tryptic
digestion, and extraction, as described [25].
The second profiling method used a proprietary, auto-
mated, multidimensional fractionation strategy (Deep Pro-
teome; Ciphergen Biosystems) run on ProteinChip Arrays
and coupled to high-throughput SELDI-TOF MS profiling.
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The method was applied to the 131 individual samples
(64 healthy, 45 benign, and 22 malignant) run in triplicate
and randomized across plates. Fractionation steps were per-
formed in 96-well filter plates on a vacuum manifold with
liquid handling using a Tecan Aquarius robot with tip-loader.
A control serum sample (Intergen) was also run (n = 5) to
monitor reproducibility. Briefly, 200L serumwas denatured
and incubated with Protein Equalizer BeadsTM in 96-well fil-
ter plates (Nunc). Flow-through was collected followed by
three elutions with high salt (E1), high organic (E2), and
denaturing buffers (E3), respectively. The flow-through was
further fractionated by hydrophobic charge induction chro-
matography (using MEP HyperCel resin) into four fractions
with flow-through (FT) and guanidine-HCl fractions (M3) re-
tained for analysis. High organic/acid and urea/acid fractions
were pooled and further separated by strong cation exchange
chromatography (using ceramic S HyperD F resin) into four
fractions (S1–S4). SDS-denatured, unfractionated serum was
also prepared for analysis (SDS). Thus, ten fractions were
generated per sample in triplicate and applied to either or
both of two SELDI chip types: CM10 (weak cation-exchange)
and/or IMAC30-Cu2+ (immobilized metal affinity capture),
depending on fraction type.
ProteinChip Arrays were read on a calibrated PCS4000 in-
strument (Ciphergen Biosystems) with automated chip load-
ing, sample tracking, reading, and spectral processing con-
trolled by Ciphergen Express software. Processing included
spectral baseline definition, smoothing, and normalization
based on total ion current. Calibrations were made using
all-in-one protein and peptide calibrants at appropriate focus
masses. Different focus masses were used for the samples
and readings taken before and/or after formic acid treatment
depending on SELDI chip and fraction type. This generated
30 profiles per sample in triplicate, resulting in a total of
11 790 spectra. Details of the method can be found in Sup-
plementary Methods.
Spectra were processed and analyzed using the Expression
DifferenceMapping tool to define peaks (based on S/N, valley
depth, and minimum peak thresholds), calculate peak inten-
sities and align peaks across spectra. Univariate analysis of av-
erage peak intensities between clinical groups was performed
using a Bonferroni-corrected p value cut-off (p < 0.000041)
and an area under theROCcurve (AUC) cut-off (<0.2 or>0.8)
to define discriminating peaks. A cross-bioprocessor/chip ar-
ray comparison (irrespective of sample group) was also car-
ried out to filter out false positives. Peaks were prioritized
depending upon their ability to differentiate early-stage or
late-stage cancers from benign and healthy controls. Multi-
variate analysis using classification trees was also performed
on the filtered peak list to generate diagnosticmodels and cor-
relation analysis used to identify commonly changing peaks.
2.3 MS-based protein identification
Proteins from 2D-DIGE gel spots were identified using
MALDI-TOF peptide mass fingerprinting (UnF andMARS1)
or LC-MS/MS peptide sequencing (MARS2 and PM) essen-
tially as described [25], using the same stringent criteria for
accepting positive identifications. In cases where multiple
identifications weremade from the same gel spots, all protein
groups are reported. Identification of differential SELDI-TOF
peaks was carried out essentially as described [17]. Briefly,
proteins were fractionated by LC and ultrafiltration and
identified either by direct MS/MS sequencing (<5 kDa) or
purified by SDS-PAGE prior to staining, excision, tryptic
digestion, and MS/MS (>5 kDa). One quarter of each band
was extracted from gels without digestion and reanalyzed by
SELDI-TOF MS to confirm matching of the band with the
peak of interest. Samples were analyzed on a Q-STAR XL
equipped with a PCI-1000 ProteinChip Interface (Ciphergen
Biosystems) and data searched against the SwissProt or
NCBInr databases. Peak identifications were also confirmed
using data from previous publications (Supporting Infor-
mation Table 3.3) and informed by correlation analysis
using Spearman’s rank test (Supporting Information
Table 3.4).
2.4 ELISA validation
Serum CA125 concentrations were measured as part
of UKOPS and UKCTOCS using a robust electro-
chemiluminescence sandwich immunoassay on an Elec-
sys 2010 analyzer (Roche Diagnostics) with the two mono-
clonal antibodies OC125 and M11 (Fujirebio Diagnostics).
Apolipoprotein A-IV (APOA4) was measured in duplicate
using an in-house developed double antibody ELISA as de-
scribed [26], and using a 1:7500 dilution of serum. Other
analytes were measured in serum in duplicate using com-
mercial ELISA kits according to the manufacturers’ instruc-
tions. These were human vitamin D binding protein (VDBP)
ELISA Kit (1:40 000 dilution; Immundiagnostik), human 1-
Antitrypsin (A1AT) ELISA Kit (1:240 000 dilution; Immundi-
agnostik), and Quantikine human secretory leukocyte pro-
tease inhibitor (SLPI) Immunoassay (1:20 dilution; R&D).
For duplicate readings of the same samples, assays gave av-
erage CVs of 4.1% (CA125), 2.7% (APOA4), 13.8% (VDBP),
10.5% (A1AT), and 8.2% (SLPI). GraphPad Prism and Stata
softwarewere used for analysis of ELISA data and for combin-
ing markers by multivariate logistic regression. For normally
distributed data, the Student t test was used to assess sig-
nificance of differences; otherwise the Mann–WhitneyU-test
was used. Fisher’s exact test was used to assess significance
of associations for noncontinuous variables and correlation
analysis used Spearman’s rank test. p values<0.05 were con-
sidered significant. Receiver operating characteristic (ROC)
curves were constructed for each marker and their combina-
tions from multivariate logistic regression analysis to assess
diagnostic accuracy in differentiatingmalignant from benign
neoplasms.
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3 Results
3.1 2D-DIGE/MS profiling for identification of
candidate markers
A total of 934 matched protein features were detected in
2D-DIGE images for the unfractionated sera (see Support-
ing Information Fig. 3). Of these, 39 were upregulated
and two downregulated when comparing the malignant
and healthy groups. Ten features were upregulated when
comparing the malignant and benign groups, with five
features overlapping. Across two 2D-DIGE experiments
examining two sets of separately MARS-immunodepleted
samples, 993 and 1268 matched features were detected,
with more lower abundance features apparent than in
the unfractionated sera (Supporting Information Fig. 3).
Quantitative analysis showed 61 spots displaying differential
abundance between the malignant and healthy groups
and 58 between the malignant and benign groups, with
47 overlapping. For the Proteominer-enriched samples,
967 features were detected, and again, lower abundance
features were apparent. Forty-five spots displayed differential
abundance between the malignant and healthy groups and
27 between the malignant and benign groups, with 11
overlapping.
Differentially abundant protein spots (n = 196 with
1.5 average-fold change and p < 0.01) were targeted for
MS-based protein identification that gave a total of 178
confident identifications, representing 56 unique gene
products (see Supporting Information Table 2). As expected,
multiple isoforms of some proteins were detected in
different spots, while numerous spots contained more than
one protein, making it difficult to attribute abundance
changes to a specific protein. The proteins identified were
mainly abundant serum proteins, including known acute
phase reactants such as AHSG, HP, ITIH4, SERPINA1, and
SERPINA3 (upregulated in malignant), immunoglobulins
(generally upregulated in malignant), complement com-
ponents (mixed regulation), coagulation proteins (mixed
regulation), apolipoproteins, and other transport proteins
(generally downregulated in malignant). Several of these had
been targeted for immunodepletion using MARS, indicating
that depletion was not complete and signifying that caution
should be taken in selecting such candidates for further
verification. Notably, several cellular proteins were identified
as differentially expressed that are not normally observed
in serum using gel-based profiling approaches. These
included CCDC88C, KIF15, PCNT, PITPNA, PPL, RAB2B,
RALGAPA1, TBX3, and VCL. However, several of these were
colocalized with other proteins in the same spot. The most
promising candidates that were up- or downregulated in
cancer versus both the benign and healthy groups and were
identified as the only protein in at least one gel spot were
A2M, APOA4, C4A, CFB, CFHR2, FGG, HP, HPR, PITPNA,
SERPINA1, SERPINC1, TF, and GC/VDBP.
3.2 SELDI-TOF profiling for identification of
candidate markers
Multiple fractions of 131 individual serum samples in tripli-
cate were generated using the Deep Proteome strategy and
the fractions profiled using high-throughput SELDI-TOFMS,
generating a total of 1786 aligned peak clusters across the
whole dataset. Using data from 5 runs of control serum, the
average CV for 33 randomly selected peaks from one frac-
tion run on a CM10 chip was 16.4% ± 6.8%, demonstrating
acceptable workflow reproducibility. For all peaks across all
fractions and chip types, the average CV was 30% ± 10.5%,
with the IMAC30 chips giving greater variance. Average peak
intensities were compared between clinical groups to define
potential markers with a total of 528 differences (p < 0.05)
identified from pairwise comparisons of malignant, benign,
healthy, early-stage malignant, late-stage malignant, healthy
plus benign, and between bioprocessors (see Supporting In-
formation Table 3.1). The data were filtered using a conserva-
tive Bonferroni-corrected p value cut-off (p < 0.000041) and
a ROC curve AUC cut-off (<0.2 or >0.8) to define 88 dis-
criminatory peaks (see Supporting Information Table 3.2).
These peaks were also used in a multivariate analysis using
classification trees to build models that could discriminate
the clinical groups and to aid in peak prioritization. The best
model (a combination of peaks S-13070, E-4629, E-5066, E-
43409, and S-29201) gave 82% sensitivity and 91% specificity
in discriminating M and B. Peaks were then prioritized ac-
cording to their ability to discriminate early-stage cancers and
also to differentiate from the benign group.
Identities were ascribed to the peaks following MS/MS-
based analysis and from previously published work (see ref-
erences in Table 2), and were also informed by a corre-
lation analysis examining coregulation. All but ten of the
88 peaks were confidently or putatively identified as abun-
dant serum proteins and modified forms thereof. Modi-
fied forms included different proteolytic products, PTMs,
oligomeric forms, different charge states, and adducts (see
Table 2 and Supporting Information Table 3.3). The pro-
teins were derived from 17 gene products. Apolipoproteins
APOA1, APOA2, and APOA4 were found to be downregu-
lated in the malignant group, as were A2M, TF (transferrin),
and TTR (transthyretin), while the known acute phase reac-
tants A1AT/SERPINA1, SERPINC1, SAA1, SAA2, and SAA4
were upregulated, as were B2M, VDBP, IGFBP4, RNASE4,
and SLPI.
3.3 Initial validation of candidate markers for
differential diagnosis of ovarian cancer
CandidatesAPOA4,VDBP,A1AT/SERPINA1, andSLPIwere
selected for initial validation and were measured by ELISA
in serum samples from 89 benign and 70 malignant ovar-
ian cancer cases, with the latter grouped into early-stage
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Table 2. SELDI-TOF peak characteristics, prioritization, and identification
Ave.
m/z
Priority Protein ID Gene
symbol
Refs. Ratio:
M v B
Ratio:
M v H
Ratio:
M v
H+B
Ratio:
M-early
v H
Ratio:
M-late
v H
2911 C Unknown 3.39 4.07 3.75 1.14 5.25
3446 A Unknown 0.70 0.71 0.70 0.86 0.66
4465 C Antichymotrypsin, CT SERPINA3 [37,38] 2.45 2.79 2.63 1.13 3.41
4630 C Antichymotrypsin, CT SERPINA3 [37,38] 1.73 1.94 1.85 1.30 2.15
5066 A Alpha-1-antitrypsin, CT? SERPINA1 1.80 1.96 1.89 1.52 2.18
5960 B2M 2+ B2M [39] 1.31 1.75 1.53 1.42 1.90
5998 Fibrinogen  fragment FGA 1.03 1.86 1.39 2.11 1.76
8679 B ApoAII monomer APOA2 [40] 0.71 0.64 0.66 0.89 0.57
11 240 C SAA2 -4aa SAA2 [41,42] 2.66 4.91 3.64 1.48 6.04
11 372 C IGFBP4 CT half IGFBP4 2.45 2.87 2.68 1.03 3.33
11 408 C SAA2 -2aa SAA2 [41,42] 4.46 7.98 6.02 1.64 9.28
11 462 SAA2 -1aa SAA2 [41,42] 7.20 20.36 11.61 0.83 24.93
11 465 C SAA1 -2aa SAA1 [41–43] 8.53 22.21 13.36 0.98 28.66
11 505 C SAA2 -1aa SAA2 [41,42] 6.53 22.66 11.22 1.06 27.91
11 534 C IGFBP4 CT half IGFBP4 2.33 2.86 2.61 1.20 3.39
11 548 C SAA1 -1aa SAA1 [41–43] 3.58 8.39 5.40 1.01 10.28
11 574 C SAA1 -1aa SAA1 [41–43] 4.96 7.20 6.07 1.42 7.74
11 662 SAA2 SAA2 [41,42] 5.98 11.45 8.31 1.06 13.27
11 674 C SAA2 SAA2 [41,42] 5.88 9.77 7.68 1.01 11.37
11 696 SAA1 SAA1 [41–43] 7.92 21.52 12.59 0.93 24.49
11 701 C Antileukoproteinase SLPI 1.88 1.86 1.87 1.14 2.17
11 702 C SAA1 SAA1 [41–43] 13.11 17.50 15.36 1.25 19.81
11 704 SAA1 -1aa SAA1 [41–43] 7.65 15.64 10.93 1.17 18.92
11 709 C Antileukoproteinase SLPI 2.04 1.85 1.93 0.78 2.25
11 714 SAA1 SAA1 [41–43] 4.13 6.81 5.37 0.96 8.60
11 715 SAA1 -1aa SAA1 [41–43] 5.24 7.78 6.48 0.98 10.23
11 722 C SAA1 SAA1 [41–43] 3.51 4.45 4.00 0.94 5.56
11 723 SAA1 SAA1 [41–43] 4.55 5.47 5.05 1.01 5.50
11 724 C Antileukoproteinase SLPI 2.22 2.75 2.50 1.03 3.08
11 725 SAA1 SAA1 [41–43] 3.33 3.90 3.65 0.97 4.68
11 754 C Antileukoproteinase SLPI 3.19 3.60 3.42 1.18 3.98
11 864 SAA1 SAA1 [41–43] 5.50 9.43 7.28 1.48 10.68
11 909 B2M B2M [39] 2.13 2.89 2.52 1.68 3.25
11 921 C B2M B2M [39] 1.78 2.06 1.93 1.19 2.39
12 035 C SAA1 adduct? SAA1 [41–43] 3.58 5.55 4.52 1.47 6.30
12 087 C SAA1 SPA adduct SAA1 [41–43] 2.86 4.26 3.54 1.48 4.84
12 111 C B2M SPA adduct B2M [39] 1.85 2.34 2.11 1.12 2.77
12 548 C Unknown 2.75 3.26 3.03 1.16 3.64
12 891 C SAA4 SAA4 [40] 1.97 2.18 2.09 1.18 2.45
12 937 B Unknown 1.22 1.84 1.52 1.43 1.98
13 070 A SAA4 SAA4 [40] 2.05 3.06 2.54 1.81 3.63
13 739 C TTR, ammonia loss TTR [44–46] 0.66 0.65 0.65 0.93 0.56
13 757 C TTR TTR [44–46] 0.62 0.62 0.62 0.97 0.49
13 866 C RNAse 4 RNASE4 1.51 1.36 1.42 1.13 1.45
13 961 A TTR, SPA adduct TTR [44–46] 0.70 0.67 0.68 0.81 0.61
13 986 A TTR, SPA adduct TTR [44–46] 0.70 0.64 0.66 0.80 0.58
14 056 B TTR, glutathionylated TTR [44–46] 0.72 0.62 0.66 0.79 0.56
14 083 B TTR, cysteinylated,
SPA adduct
TTR [44–46] 0.74 0.66 0.69 0.83 0.60
14 269 ApoAI, 2+ APOA1 [40,46–48] 0.88 0.71 0.77 0.89 0.67
14 350 ApoAI, 2+ APOA1 [40,46–48] 0.85 0.72 0.77 0.89 0.69
14 589 ApoAI, 2+ APOA1 [40,46–48] 0.83 0.72 0.76 0.89 0.68
17 095 A ApoAII dimer -2 Gln APOA2 0.62 0.55 0.58 0.69 0.52
17 230 A ApoAII dimer -Gln APOA2 0.63 0.58 0.60 0.77 0.52
18 001 A ApoAII dimer (+propeptide?) APOA2 0.66 0.62 0.64 0.73 0.59
(Continued)
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Table 2. Continued
Ave.
m/z
Priority Protein ID Gene
symbol
Refs. Ratio:
M v B
Ratio:
M v H
Ratio:
M v
H+B
Ratio:
M-early
v H
Ratio:
M-late
v H
21 497 ApoAIV 2+ APOA4 0.79 0.64 0.70 0.64 0.65
21 682 ApoAIV 2+ APOA4 0.67 0.55 0.59 0.62 0.54
21 714 ApoAIV 2+ APOA4 0.72 0.58 0.63 0.56 0.60
21 808 ApoAIV 2+ APOA4 0.77 0.64 0.69 0.57 0.67
25 621 A VDBP, 2+ VDBP 1.63 1.75 1.70 1.38 1.80
28 559 B ApoAI APOA1 [40,46–48] 0.87 0.71 0.77 0.86 0.67
28 697 B ApoAI APOA1 [40,46–48] 0.86 0.72 0.77 0.87 0.69
29 201 B ApoAI APOA1 [40,46–48] 0.85 0.72 0.77 0.84 0.70
29 394 B ApoAI APOA1 [40,46–48] 0.85 0.73 0.78 0.84 0.71
35 763 A ApoAI + ApoAIV, 2+ APOA1 0.80 0.70 0.74 0.63 0.73
39 411 C Unknown 2.01 2.28 2.16 1.05 2.57
40 617 Unknown 3.46 5.30 4.35 1.25 6.25
41 956 B ApoAI + TT cysteinylated APOA1 0.61 0.52 0.56 0.78 0.44
43 409 A ApoAIV APOA4 0.68 0.55 0.60 0.57 0.55
43 429 ApoAIV APOA4 0.72 0.56 0.61 0.60 0.55
44 662 A ApoAIV APOA4 0.84 0.72 0.77 0.65 0.75
47 287 ApoAI + albumin, 2+ APOA1 0.72 0.60 0.64 0.83 0.53
50 764 A Alpha-1-antitrypsin SERPINA1 1.59 1.60 1.59 1.19 1.69
51 213 A VDBP VDBP 1.63 1.73 1.69 1.27 1.83
53 296 C related to VDBP 1.89 2.22 2.07 1.52 2.38
56 481 ApoAI dimer APOA1 [40,46–48] 0.82 0.65 0.71 0.76 0.63
75 809 C Unknown 0.76 0.71 0.73 1.00 0.61
79 221 Transferrin TF [46,49] 0.84 0.83 0.83 1.03 0.76
80 641 C Transferrin TF [46,49] 0.74 0.65 0.68 0.96 0.53
86 919 ApoAI trimer APOA1 [40,46–48] 0.78 0.56 0.63 0.58 0.57
94 544 B ApoAI + albumin APOA1 0.73 0.62 0.67 0.80 0.56
101 711 A Alpha-1-antitrypsin dimer SERPINA1 1.38 1.52 1.45 1.22 1.56
116 137 ApoAI tetramer APOA1 [40,46–48] 0.74 0.50 0.58 0.48 0.54
117 380 B VDBP + albumin VDBP 2.05 2.41 2.24 1.39 2.67
123 153 C Unknown 0.71 0.67 0.68 0.88 0.60
175 448 B Alpha-2-macroglobulin A2M 0.59 0.51 0.54 0.78 0.43
184 620 B VDBP + albumin dimer VDBP 2.41 3.40 2.91 1.94 3.66
264 556 C Unknown 0.63 0.66 0.64 1.05 0.53
295 826 B Unknown 0.68 0.58 0.62 0.65 0.56
Average m/z values shaded gray were peaks used in classification tree models. Priority column corresponds to the following definition:
A = peak intensity different in early stage and also differentiates from benign; B = peak intensity different in early stage and does not
differentiate from benign; C = peak intensity different only in late stage. For Protein ID; bold versus plain font = increased confidence in
ID; gray shading = ID based on experimental data and known modifications/dimer status; plain font and no shading = prediction only
or inference from literature. Abbreviations: aa, amino acid; Apo, apolipoprotein; B2M, beta-2-microglobulin; CT, C-terminal; SAA, serum
amyloid A; SPA, sinapinic acid; TTR, transthyretin; VDBP, vitamin D binding protein. M, malignant; B, benign; H, healthy. At least one ratio
in the five comparisons was significant (p < 0.000041) and had an area under the ROC curve <0.2 or >0.8. See, Supporting Information
Table 3 for more detail.
(FIGO I and II) and late-stage (FIGO III and IV) cancers.
Thus, samples from 44 and 48 independent benign and ma-
lignant cases, respectively, were analyzed in addition to those
used for discovery experiments. All candidate markers were
able to significantly discriminate late-stage malignant cases
from benign controls in agreement with the discovery data
(Fig. 1). Only SLPI and APOA4 discriminated early-stage ma-
lignant cases from benign cases, while SLPI and A1AT also
separated early from late-stage disease (p = 0.0007 and p
= 0.0031, respectively). None of the candidate markers was
as good as CA125 in discriminating malignant from benign
cases (Fig. 1).
Candidate markers were next combined using multivari-
ate logistic regression and ROC curves constructed to assess
the value of combinedmarker panels for the differential diag-
nosis of ovarian cancer (Table 3). No combination of markers
was better than CA125 alone for discriminating the malig-
nant versus benign groups that had an AUC of 0.884, al-
though the best model without CA125 (combining VDBP,
APOA4, and SLPI) did have a respectable AUC of 0.834. No-
tably, most combined models were better than CA125 alone
at discriminating early from late-stage cancers with a model
that combined CA125, VDBP, and A1AT giving an AUC of
0.806.
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Figure 1. Scatter plots of serum assay values for SLPI, VDBP, A1AT/SERPINA1, APOA4, and CA125 in a set of 89 benign and 70 malignant
ovarian cancer cases separated by FIGO stage (I + II and III + IV). Bars indicate the median value with interquartile range. For normally
distributed data, the Student t test was used to assess significance of differences; otherwise the Mann–Whitney U-test was used.
3.4 Testing SLPI as an early marker of ovarian cancer
SLPI, the best performing candidate in the clinical cases was
further tested as an early marker and compared with CA125
using a nested case control set from within the UKCTOCS
and comprising pairs of serum samples taken at different
times prior to the diagnosis of ovarian cancer (Supporting
Information Table 1). Thus, 148 serum samples came from
74women, 19 of whowere subsequently diagnosed with Type
I or borderline (Type I/BL) ovarian cancer, 30 of who were
subsequently diagnosed with Type II ovarian cancer and 25
noncancer controls. The samples were also grouped by time
to diagnosis, with a 3–14 months (designated "late") and a
>32 months (designated "early") prediagnosis group.
CA125 performed well in detecting cancers within 3–14
months of diagnosis (Fig. 2A), and was superior for the Type
II cases that were predominantly high grade serous and en-
dometrioid cancers (AUC = 0.78 for Type I/BL "late"; AUC
= 0.89 for Type II "late"). As expected, AUC’s for CA125 were
lower for the "early" prediagnosis samples, and notably worse
for Type II cases (AUC = 0.70 for Type I/BL "early"; AUC =
0.61 for Type II "early"). Serum SLPI levels did not signifi-
cantly discriminate cases and controls in either prediagnosis
time group, although its levels were significantly increased
in the "late" versus "early" time group samples for the Type
II cases (Fig. 2B). Combining CA125 and SLPI showed no
improvement in the ability to detect preclinical cancer with
or without additional epidemiological and lifestyle factors
(not shown).
4 Discussion
Two complementary protein-profiling methods were applied
to serum samples taken from patients diagnosed with ma-
lignant or benign epithelial ovarian cancer and healthy con-
trols for the unbiased identification of candidate biomark-
ers for differential diagnosis of ovarian cancer. It was some-
what disappointing that mostly abundant proteins were iden-
tified as being differentially expressed between the sample
groups despite the use of strategies that employed exten-
sive fractionation and immunodepletion. This highlights the
very large dynamic range and complexity of protein expres-
sion in serum.While undoubtedly improving dynamic range,
it is worth mentioning the limitations of serum immun-
odepletion and protein equalization in proteomics discovery
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Table 3. Performance of combined marker models for differential diagnosis
Model No. No. markers Marker 1 Marker 2 Marker 3 Marker 4 Marker 5 AUC M
versus B
AUC Early
versus late
28 1 VDBP 0.598 0.659
29 1 APOA4 0.661 0.517
30 1 A1AT 0.661 0.701
22 2 VDBP A1AT 0.665 0.759
24 2 APOA4 A1AT 0.68 0.716
21 2 VDBP APOA4 0.704 0.677
13 3 VDBP APOA4 A1AT 0.718 0.758
15 3 VDBP A1AT SLPI 0.755 0.767
23 2 VDBP SLPI 0.758 0.738
26 2 A1AT SLPI 0.758 0.72
31 1 SLPI 0.763 0.704
16 3 APOA4 A1AT SLPI 0.824 0.717
6 4 VDBP APOA4 A1AT SLPI 0.825 0.764
25 2 APOA4 SLPI 0.831 0.7
14 3 VDBP APOA4 SLPI 0.834 0.748
4 4 CA125 VDBP A1AT SLPI 0.856 0.792
20 2 CA125 SLPI 0.856 0.721
12 3 CA125 A1AT SLPI 0.857 0.752
9 3 CA125 VDBP SLPI 0.858 0.765
8 3 CA125 VDBP A1AT 0.862 0.806
17 2 CA125 VDBP 0.864 0.727
2 4 CA125 VDBP APOA4 A1AT 0.866 0.802
10 3 CA125 APOA4 A1AT 0.867 0.756
7 3 CA125 VDBP APOA4 0.869 0.737
18 2 CA125 APOA4 0.869 0.65
1 5 CA125 VDBP APOA4 A1AT SLPI 0.871 0.782
5 4 CA125 APOA4 A1AT SLPI 0.872 0.762
11 3 CA125 APOA4 SLPI 0.873 0.716
3 4 CA125 VDBP APOA4 SLPI 0.877 0.769
19 2 CA125 A1AT 0.88 0.733
27 1 CA125 0.884 0.641
Models were constructed and tested using multivariate logistic regression in Stata software. Areas under the ROC curves (AUC) are
shown for all possible combinations of markers and shown in ascending order for comparison of malignant versus benign cases. Model
performance for early versus late-stage disease is also shown.
experiments. Particularly, both methods may potentially re-
move diagnostic proteins bound to abundant carrier proteins
such as albumin, while equalization seems conceptually at
odds with the ability to accurately compare starting protein
levels across sample groups. There is the assumption that pro-
tein levels in the starting material are preserved after equal-
ization that may not be the case. However, we do note that a
subset of the same differentially expressed proteins was iden-
tified using the two different profiling methods, suggesting
that such an effect is not prevalent. Despite the limited cov-
erage, several cellular, nonsecreted proteins were identified
as being differentially regulated and the phospholipid trans-
fer protein PITPNA was the top candidate in this class for
discriminating malignant and benign cases. PITPNA has not
been previously reported as a cancer biomarker and warrants
further investigation.
Notably, four of the differentially expressed proteins iden-
tified (namely APOA1, B2M, TF, and TTR) are the four
serum proteins used with CA125 in the Ova1 diagnostic test
[6, 10, 27], approved for use in combination with physician
assessment to determine if an ovarian tumour on ultrasound
warrants referral for surgery. These findings thus add confi-
dence to the discovery and partly support the validity of the
markers used in the Ova1 test. Whilst the performance of
the non-CA125 Ova1 markers without CA125 has not been
evaluated directly, one study showed that the Ova1 test de-
tected over 50% of malignancies missed by CA125 alone [28].
Without inclusion of physician’s assessment, the sensitivity
and specificity of CA125 alone (cut-off 35 U/mL) were 77 and
73%, respectively, versus 93 and 43% using the Ova1 test.
Thus, inclusion of APOA1, B2M, TF, and TTR improve the
sensitivity of the test at a significant cost to specificity.
Herein, an increase in known acute-phase proteins was
observed in the malignant versus benign (and healthy) sam-
ples. This suggests that malignancy is accompanied by an
increased inflammatory response versus the benign con-
ditions. Whether this response is specific to ovarian ma-
lignancy would require further investigation, for example,
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Figure 2. Box and whisker plots showing serum assay values
for CA125 (A) and SLPI (B) in a set of 148 prediagnosis serum
samples and matched noncancer controls. Cases were separated
into Type I plus borderline (Type I/BL) disease and Type II dis-
ease based upon morphology and grade. Paired samples from
each case were taken 2–14 months prior to diagnosis and termed
"late" and >36 months prior to diagnosis and termed "early."
Controls were matched based on Type II cases. Boxes indicate
the median value with interquartile range and whiskers show the
5th and 95th percentiles. The cross indicates the mean value for
each group. The Student t test was used to assess significance
of differences for the SLPI data, which was normally distributed,
while the Mann–Whitney U-test was used for the CA125 data.
comparing these candidatemarkers inmalignant and benign
ovarian cancer cases versus inflammatory disease cases such
as arthritis. Similarly, therewas a general decrease in proteins
reflective of nutritional status such as serum apolipoproteins
and other serum transport proteins. Indeed the best candidate
markers for differential diagnosis of ovarian cancer identified
here fell into these functional categories, including proteins
A1AT, APOA4, and VDBP that were selected for further eval-
uation as ovarian cancer biomarkers. It may also be the case
that SLPI (the fourth candidate tested) is also raised during
inflammation. SLPI is expressed in a tissue-specific manner
by cells at a variety of mucosal surfaces and is an inhibitor
of the proteases elastase, cathepsin G and trypsin [29]. To-
gether with A1AT it is thought to protect mucosal surfaces,
particularly in the lung, from damage by neutrophil elastase
[30]. SLPI has been tested as an ovarian cancer biomarker
previously, with reasonable accuracy for differential
diagnosis of malignant disease [31]. In another case-control
study, serum SLPI showed stage-specific elevation, although
was not selected for inclusion in the multimarker models
that were tested [32]. Our data support these previous find-
ings and suggest that SLPI may have some utility as a serum
marker for ovarian cancer, although combining SLPI with
CA125 did not improve on CA125 as a single marker. Serum
SLPI was also poor at predicting preclinical ovarian cancer
cases, although there was evidence of a rise in levels in cases
toward diagnosis. VDBP has not previously been reported
as an ovarian cancer marker, although using a peptide pro-
filing approach, endogenous proteolytic fragments of VDBP
were identified in ascites fluid from ovarian cancer patients,
but not from control patients with liver cirrhosis [33]. The
authors however reported no difference in serum VDBP pro-
tein levels (by ELISA) between the ovarian cancer cases and
healthy controls. Finally, plasma APOA4 was previously re-
ported to be lower in samples from cases of malignant ver-
sus benign ovarian neoplasms, but did not add independent
diagnostic information to CA125 [34]. Indeed, no combina-
tion of the candidate markers reported here was better than
CA125 alone at differentiating malignant from benign ovar-
ian neoplasms. However, it is important to note that CA125
performs well in this cohort (92% sensitivity, 70% specificity
at a 37 U/mL cut-off). As we have previously reported [35],
this likely reflects the fact that samples were obtained from
women referred to specialist gynaecologic cancer centres, a
proportion of which will have been referred based on elevated
CA125. Thus, the performance of CA125 can be exaggerated
in these types of study, as previously highlighted [36]. The
better-than-expected performance of CA125 may also in part
be explained by the inclusion of only postmenopausal women
in our cohort and restriction of cases to only primary invasive
epithelial cancers.
In conclusion, we have identified and tested several can-
didate serum markers of ovarian cancer that are presumed
indicators of inflammation and nutritional status. This sug-
gests that there are differences in the body’s response to
the presence of a malignant versus benign ovarian cancer.
Although the markers could accurately discriminate ma-
lignant from benign cases, none were as good as CA125
either alone or in combination having low specificities,
and did not add to the performance of CA125, which was
high in this cohort. Despite this, further independent val-
idation of these candidate markers is warranted, using a
more randomly selected patient cohort, for example, any
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woman referred based on an unusual transvaginal ultrasound
result.
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